CAMBRIDGE, Mass. , Sept. 27, 2022 (GLOBE NEWSWIRE) — Voyager Therapeutics, Inc. (Nasdaq: VYGR), a gene therapy and neuroscience company developing life-changing treatments and next-generation adeno-associated virus (AAV) capsids, today announced that management will participate in the following

Reader Interactions

Leave A Reply